Clinical trial
A Phase 1, Multicenter, Open-label Study of BMS-986403 in Subjects With Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
NCT05244070 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Multicenter, Open-label Study of BMS-986403 in Subjects With Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- September 14, 2022
- Completion date
- May 4, 2023
- Enrollment
- 5 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.